Circulating Tumour DNA in Muscle-Invasive Bladder Cancer
AbstractCirculating tumour DNA (ctDNA) is an attractive tool in cancer research, offering many advantages over tissue samples obtained using traditional biopsy methods. There has been increasing interest in its application to muscle-invasive bladder cancer (MIBC), which is recognised to be a heterogeneous disease with overall poor prognosis. Using a range of platforms, studies have shown that ctDNA is detectable in MIBC and may be a useful biomarker in monitoring disease status and guiding treatment decisions in MIBC patients. Currently, with no such predictive or prognostic biomarkers in clinical practice to guide treatment strategy, there is a real unmet need for a personalised medicine approach in MIBC, and ctDNA offers an exciting avenue through which to pursue this goal. In this article, we present an overview of work to date on ctDNA in MIBC, and discuss the inherent challenges present as well as the potential future clinical applications. View Full-Text
A printed edition of this Special Issue is available here.
Share & Cite This Article
Tan, M.P.; Attard, G.; Huddart, R.A. Circulating Tumour DNA in Muscle-Invasive Bladder Cancer. Int. J. Mol. Sci. 2018, 19, 2568.
Tan MP, Attard G, Huddart RA. Circulating Tumour DNA in Muscle-Invasive Bladder Cancer. International Journal of Molecular Sciences. 2018; 19(9):2568.Chicago/Turabian Style
Tan, Melissa P.; Attard, Gerhardt; Huddart, Robert A. 2018. "Circulating Tumour DNA in Muscle-Invasive Bladder Cancer." Int. J. Mol. Sci. 19, no. 9: 2568.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.